Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Quackenbush

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
British Journal of Cancer|July 23, 2013
Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant modelJ J Arcaroli, K S Quackenbush, A Purkey, et al.
Oncotarget|January 18, 2018
The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapyJustin Greene, Anna Nguyen, Stacey M Bagby, et al.
Molecular Cancer Therapeutics|July 21, 2018
Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling MechanismsAaron J Scott, John J Arcaroli, Stacey M Bagby, et al.
International Journal of Cancer|September 23, 2014
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant modelEun-Kee Song, W M Tai, Wells A Messersmith, et al.
International Journal of Cancer|July 9, 2015
A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancerJohn J Arcaroli, W M Tai, Ryan McWilliams, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
British Journal of Cancer|July 23, 2013
Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant modelJ J Arcaroli, K S Quackenbush, A Purkey, et al.
Oncotarget|January 18, 2018
The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapyJustin Greene, Anna Nguyen, Stacey M Bagby, et al.
Molecular Cancer Therapeutics|July 21, 2018
Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling MechanismsAaron J Scott, John J Arcaroli, Stacey M Bagby, et al.
International Journal of Cancer|September 23, 2014
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant modelEun-Kee Song, W M Tai, Wells A Messersmith, et al.
International Journal of Cancer|July 9, 2015
A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancerJohn J Arcaroli, W M Tai, Ryan McWilliams, et al.
Pageof 2